News
The FDA Just Approved an RSV Vaccine -- and It Isn't From Moderna or Pfizer
Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) are two healthcare companies aiming to produce a vaccine for the respiratory syncytial virus (RSV). In trials, their vaccine candidates have been
Here's Why Eli Lilly's Alzheimer's Drug Could Be the Real Deal
Eli Lilly (NYSE: LLY) has a potential Alzheimer's treatment in donanemab that shows a lot of promise. The company reported data from a recent trial which demonstrated some encouraging results, and
This FDA Nod Is a Game Changer for Patients: Could It Equal Billions for Vertex Pharmaceuticals?
Vertex Pharmaceuticals (NASDAQ: VRTX) is already a rock star in the world of cystic fibrosis (CF) treatment. The company's drugs have been life-changing for children and adults living with the
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Is the Worst Over for Novavax?
In the early days of the COVID-19 pandemic, Novavax (NASDAQ: NVAX) took center stage. The biotech company became one of the first to enter clinical trials with a coronavirus vaccine candidate. And
Why Shares of MannKind Are Up Wednesday
Shares of MannKind (NASDAQ: MNKD) were up 15.6% Wednesday morning after the company released first-quarter earnings after the market closed on Tuesday.
The company specializes in treating endocrine
2 Cathie Wood Stocks That Can Get You Through Any Recession
Economists at the U.S. Federal Reserve recently uttered the dreaded "R" word. They are now predicting a recession will come later this year. Investors have been bracing for this possibility for a
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Exelixis (EXEL) Q1 2023 Earnings Call Transcript
Image source: The Motley Fool.
Exelixis (NASDAQ: EXEL)Q1 2023 Earnings CallMay 09, 2023, 5:00 p.m. ET
Operator
Source Fool.com
MacroGenics (MGNX) Q1 2023 Earnings Call Transcript
Image source: The Motley Fool.
MacroGenics (NASDAQ: MGNX)Q1 2023 Earnings CallMay 09, 2023, 4:30 p.m. ET
Operator
Source Fool.com
MannKind (MNKD) Q1 2023 Earnings Call Transcript
Image source: The Motley Fool.
MannKind (NASDAQ: MNKD)Q1 2023 Earnings CallMay 09, 2023, 5:00 p.m. ET
Operator
Source Fool.com
Invitae (NVTA) Q1 2023 Earnings Call Transcript
Image source: The Motley Fool.
Invitae (NYSE: NVTA)Q1 2023 Earnings CallMay 09, 2023, 4:30 p.m. ET
Operator
Source Fool.com
Agenus (AGEN) Q1 2023 Earnings Call Transcript
Image source: The Motley Fool.
Agenus (NASDAQ: AGEN)Q1 2023 Earnings CallMay 09, 2023, 8:30 a.m. ET
Operator
Source Fool.com
Why Catalent Stock Was in the Red Again Today
Beleaguered healthcare stock Catalent (NYSE: CTLT) took the latest in a series of drubbings on the market Tuesday. This one wasn't as bad as those of previous sessions, although that was surely cold
Why Viking Therapeutics Stock Wobbled Today
Shares of clinical-stage biotech Viking Therapeutics (NASDAQ: VKTX) fell by as much as 4.8% on exceptionally low volume during the first hour of trading Tuesday morning. Since this mid-single-digit
Why Shares of Grifols Were Up Tuesday
Shares of Grifols (NASDAQ: GRFS) were up 11.1% on Tuesday afternoon, after being up as much as 13.1% earlier in the day. The pharmaceutical company, which makes plasma-derived medicines, released
Axsome's New Drug Is Scoring a Win. Is the Stock a Buy?
Axsome Therapeutics (NASDAQ: AXSM) stood out last year. The biotech began selling its first two products: Sunosi, a sleep disorder drug it acquired from Jazz Pharmaceuticals; and Auvelity, an
Why CRISPR Therapeutics Stock Is on Fire Today
Shares of the developmental gene-editing company CRISPR Therapeutics (NASDAQ: CRSP) were up by 12.4% on sky-high volume as of 1:46 p.m. ET Tuesday afternoon. The big gain came in response to the bio
EQS-News: Just – Evotec Biologics launches tech partnership for biosimilars development and commercial manufacturing
EQS-Adhoc: Just – Evotec Biologics enters strategic biosimilars partnership with Sandoz
EQS-News: Biotest AG: Annual General Meeting of Biotest AG elects Raimon Grifols Roura to the Supervisory Board
Is AT&T's Dividend Safe?
The biggest disappointment from AT&T's (NYSE: T) first-quarter earnings report was its dismal free cash flow.
Free cash flow is extremely important for AT&T investors, many of whom look for the
The Vanguard Group, Inc.: Horizon Therapeutics plc
Why Catalent Stock Was a Disaster Today
The struggles of contract drugmaker Catalent (NYSE: CTLT) continued on Monday, leading to a big sell-off in the company's stock. Investors were heavily discouraged by their company's latest update
Axsome Therapeutics (AXSM) Q1 2023 Earnings Call Transcript
Image source: The Motley Fool.
Axsome Therapeutics (NASDAQ: AXSM)Q1 2023 Earnings CallMay 08, 2023, 8:00 a.m. ET
Operator
Source Fool.com